US 12018057
Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
granted A61KA61K38/00A61K47/60
Quick answer
US patent 12018057 (Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases) held by Protagonist Therapeutics, Inc. expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Protagonist Therapeutics, Inc.
- Grant date
- Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 10
- CPC classes
- A61K, A61K38/00, A61K47/60